We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+6.3%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$3.29M
(-1.8%)
Cap. Flow
-$8.86M
Cap. Flow
% of AUM
-4.83%
Top 10 Holdings %
Top 10 Hldgs %
62.72%
Holding
56
New
18
Increased
15
Reduced
7
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TriNet
TNET
|
+$5.38M |
| 2 |
Option Care Health
OPCH
|
+$4.81M |
| 3 |
MeiraGTx Holdings
MGTX
|
+$3.64M |
| 4 |
Intellia Therapeutics
NTLA
|
+$3.43M |
| 5 |
Health Catalyst
HCAT
|
+$3.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$17.7M |
| 2 |
Charles River Laboratories
CRL
|
+$6.54M |
| 3 |
Tenet Healthcare
THC
|
+$5.26M |
| 4 |
Johnson & Johnson
JNJ
|
+$5.18M |
| 5 |
Alkermes
ALKS
|
+$3.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.65% |
| 2 | Industrials | 2.88% |
| 3 | Miscellaneous | 2.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LKFT
26
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
| $1.78M | 0.97% |
+40,000
| New | +$1.68M |
|
|
SGEN
27
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.54M | 0.84% |
+12,000
| New | +$1.55M |
|
28
Lifestance Health
LFST
$4.86B
| $1.43M | 0.78% |
+289,335
| New | +$1.79M |
|
29
BioCryst Pharmaceuticals
BCRX
$2.15B
| $1.34M | 0.73% |
116,732
+2,932
| +3% | +$36.6K |
|
|
FLNA
30
PUT
Filana Therapeutics
FLNA
$33.1M
| $1.21M | 0.66% |
40,900
+5,000
| +14% | +$180K |
|
|
MORF
31
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.15M | 0.63% |
+42,949
| New | +$1.17M |
|
32
Elutia
ELUT
$35.9M
| $786K | 0.43% |
+185,014
| New | +$1.16M |
|
33
Biomea Fusion
BMEA
$126M
| $690K | 0.38% |
+81,907
| New | +$699K |
|
34
BridgeBio Pharma
BBIO
$13.4B
| $678K | 0.37% |
+89,027
| New | +$852K |
|
35
Rocket Pharmaceuticals
RCKT
$382M
| $630K | 0.34% |
32,193
-167,807
| -84% | -$3.09M |
|
36
Gossamer Bio
GOSS
$67M
| $575K | 0.31% |
+3,313
| New | +$2.18M |
|
37
Evolus
EOLS
$528M
| $499K | 0.27% |
66,438
-93,762
| -59% | -$726K |
|
|
STLN
38
Starling Oncology
STLN
$666M
| $455K | 0.25% |
+275,561
| New | +$773K |
|
39
Tenaya Therapeutics
TNYA
$147M
| $215K | 0.12% |
+107,063
| New | +$261K |
|
40
Personalis
PSNL
$1.72B
| $116K | 0.06% |
+58,668
| New | +$148K |
|
41
Ardelyx
ARDX
$875M
| – | – |
-1,126,127
| Closed | -$1.34M |
|
42
Avantor
AVTR
$10.6B
| – | – |
-122,668
| Closed | -$2.4M |
|
43
Baxter International
BAX
$12.2B
| – | – |
-39,000
| Closed | -$2.1M |
|
|
44
Charles River Laboratories
CRL
$13.1B
| – | – |
-33,220
| Closed | -$6.54M |
|
45
Incyte
INCY
$25.3B
| – | – |
-40,450
| Closed | -$2.7M |
|
|
46
Johnson & Johnson
JNJ
$644B
| – | – |
-31,704
| Closed | -$5.18M |
|
47
Maravai LifeSciences
MRVI
$1.02B
| – | – |
-8,540
| Closed | -$218K |
|
48
Omnicell
OMCL
$1.48B
| – | – |
-30,700
| Closed | -$2.67M |
|
49
ProQR Therapeutics
PRQR
$262M
| – | – |
-1,716,290
| Closed | -$1.28M |
|
50
CALL
Prothena Corp
PRTA
$423M
| – | – |
-53,100
| Closed | -$3.22M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2022 Portfolio in Review
As of Q4 2022, Prosight Management held 56 positions worth $183M, down 1.8% from $187M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management withdrew a net $8.86M in Q4 2022, closing 16 positions and reducing 7 holdings. Its most notable exit was Charles River Laboratories, an estimated $6.54M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Prosight Management opened a new position in TriNet worth $5.29M.
- Prosight Management's largest Q4 2022 buy was TriNet: 78,000 shares worth $5.29M.
- Prosight Management added most to MeiraGTx Holdings in Q4 2022, an estimated $3.64M increase.
- Prosight Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $17.7M.
- Prosight Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $6.54M.
- Prosight Management's ten largest holdings make up 63% of its $183M portfolio in Q4 2022.
- Prosight Management opened 18 new positions and closed 16 in Q4 2022.
- Prosight Management's portfolio value fell 1.8% quarter-over-quarter to $183M.
Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.